<code id='EEAE812724'></code><style id='EEAE812724'></style>
    • <acronym id='EEAE812724'></acronym>
      <center id='EEAE812724'><center id='EEAE812724'><tfoot id='EEAE812724'></tfoot></center><abbr id='EEAE812724'><dir id='EEAE812724'><tfoot id='EEAE812724'></tfoot><noframes id='EEAE812724'>

    • <optgroup id='EEAE812724'><strike id='EEAE812724'><sup id='EEAE812724'></sup></strike><code id='EEAE812724'></code></optgroup>
        1. <b id='EEAE812724'><label id='EEAE812724'><select id='EEAE812724'><dt id='EEAE812724'><span id='EEAE812724'></span></dt></select></label></b><u id='EEAE812724'></u>
          <i id='EEAE812724'><strike id='EEAE812724'><tt id='EEAE812724'><pre id='EEAE812724'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:entertainment    - browse:83
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand. Adobe

          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

          advertisement

          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore